###### Strengths and limitations of this study

-   This study is the first attempt to evaluate whether there were better correlations between cancer drug prices and clinical outcomes in a setting where central price negotiations are mandatory for every new medicine.

-   This understanding is important for cancer policy decisions.

-   In our analysis, the relationship between the clinical outcome and cost of anticancer drugs was ascertained by a simple linear regression model.

-   Clinical outcome, which was the dependent variable, was expressed as absolute or per cent differences in outcomes between treatment and control groups.

-   The main limitations of our study concern data completeness on clinical outcome and price. We used, as an estimate of benefit, data from pivotal trials retrieved from European Public Assessment Reports.

Background {#s1}
==========

High costs of cancer drugs and resulting financial toxicity to cancer patients are now a well-recognised problem in cancer policy throughout the world.[@R1] Various solutions are being proposed to address this problem, of which price negotiations with pharmaceutical companies are proposed as an important strategy, especially in the USA.[@R9] Because the Medicare is not allowed to negotiate prices with companies, despite being mandated to cover for every US Food and Drug Administration (FDA)-approved drug, various experts have argued that this is the reason for high drug prices in the USA. Indeed, cancer drug prices far exceed the costs of their development[@R12]; such negotiations might help to lower the prices of cancer drugs as evidenced by lower cost of cancer drugs in other developed countries compared with the USA.

However, little is known about if such negotiations would lead to better correlation between cancer drug prices and the benefits they provide. Studies have shown that drug prices do not correlate with clinical benefits for cancer drugs approved by the FDA, even though such studies have not taken central price negotiations into account.[@R13] Countries, such as the UK and Italy, negotiate prices and hence, the correlations might be different.

In Italy, drug price negotiation based on cost-effectiveness evaluation has been mandatory since 2001 for all medicines reimbursed by the National Health Service (NHS).[@R15] We analysed the correlation between the prices of cancer drugs in Italy with their clinical outcomes to test the hypothesis that central price negotiations lead to better alignment of prices and benefits.

Methods {#s2}
=======

Identification of the study sample {#s2-1}
----------------------------------

All new drugs approved by the European Medicines Agency (EMA) via a centralised procedure between January 2010 and June 2016 for the treatment of either solid or haematological cancers were initially identified. Generics, biosimilars, interferons and granulocyte-colony stimulating factors were excluded. Only anticancer drugs with pivotal trials based on overall survival (OS), progression-free survival (PFS) or objective response rate (ORR) and with prices that were officially negotiated in Italy by 31 December 2016 were included in the cohort for analyses.

Data extraction {#s2-2}
---------------

Information on the clinical outcomes (in terms of median OS, median PFS and ORR) was extracted by two coinvestigators (FB-A and RP) from pivotal trials that compared new treatments with controls as reported in the European Public Assessment Reports (EPARs) (summary table of the main study, Section 2.5.2) publicly available on the EMA website ([www.ema.europa.eu](www.ema.europa.eu)). Survival times were expressed in weeks, and the reported OS and PFS were transformed when necessary. Information on therapeutic indication and tumour type were also retrieved.

Drug prices {#s2-3}
-----------

The cost of a full course or 1-year treatment was estimated by two coinvestigators (NM and IE) on the basis of the negotiated official ex-factory price (in euros) of drug packages, as published in the Official Gazette of the Italian Republic ([www.gazzettaufficiale.it](www.gazzettaufficiale.it)) and taking into account the posology as reported in the summary of product characteristics (SPC). To compare prices of drugs with different schedules, in the text, we refer to drug prices as the cost of a full course or a 1-year treatment. A further estimate took into account additional compulsory rebates[@R17] or extradiscounts that were agreed with pharmaceutical companies; this information is confidential to the public but is released to procurement stations within the Italian NHS (eg, regions, hospitals and local health units).

Statistical analysis {#s2-4}
--------------------

The following variables were extracted and analysed descriptively: year of approval, therapeutic indication, type of treatment and control groups, outcome data, official and confidential costs per treatment (1 year or a full course) and regulatory information (conditional/under exceptional circumstances approval or orphan drug status).

The relationship between the clinical outcomes and cost of anticancer drugs was ascertained by a simple linear regression model. Clinical outcome, which was the dependent variable, was expressed as absolute or percent differences in outcomes between treatment and control groups. Regression coefficients β, their levels of significance p and the coefficients of determination R^2^ were reported for each model.

We also performed several sensitivity analyses to test the robustness of the results. Specifically, we performed multiple linear regression with tumour type as the independent variable to take into account potential differences due to tumour characteristics. Moreover, we also repeated the analysis after excluding negative outcome differences (in two cases, one of the outcomes was inferior in the group receiving the new drug than in the comparison group) and actively controlled trials (considering only placebo-controlled trials). Subgroup analysis by tumour type was also attempted as exploratory analysis when a minimum number of two anticancer drugs within the same tumour type setting were observed. Outlier cases were not excluded from the analyses, but their impact was evaluated and reported when relevant as a separate analysis. All statistical analyses were performed using STATA (StataCorp, V.14.0)

Patient and public involvement {#s2-5}
------------------------------

Patients have not been involved in the development of the research question or the design of this study. However, results of this analysis will be disseminated throughout public conferences, with statements summarising our results, and with an open access to the published report posted in our institutional websites

Results {#s3}
=======

From 2010 to mid-2016, 45 new anticancer drugs for 56 different oncology indications were approved via centralised procedures by the EMA. For 40 new anticancer drugs (47 indications), the basis for the approval was a pivotal trial adopting OS, PFS or ORR as a primary outcome; the price negotiation was completed by December 2016 for only 30 new anticancer drugs (35 indications) which are included in our analysis ([table 1](#T1){ref-type="table"}). Seven drugs received orphan drug status by the EMA and two (vandetanib and crizotinib) received conditional approval. Of the 35 oncology indications tested in 35 different pivotal trials which were all controlled clinical trials, the most common indications were melanoma (7 out of 35), followed by haematological cancer (6 out of 35) and non-small-cell lung cancer (4 out of 35). In 15 such trials (43%), placebo was used as the control arm. Of the 35 indications, data on OS, PFS and ORR were available for 17, 29 and 29 indications, respectively. Each drug--indication pair contributed to one or more of these analyses, depending on which outcomes were reported in the EPAR.

###### 

Characteristics of the 30 anticancer drugs included in the analysis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medicine name   Active substance             Clinical setting                                                                                                                                       Treatment group                                                       Control group                                                       PFS TRT (median in weeks)   PFS CRT (median in weeks)   OS TRT (median in weeks)   OS CRT (median in weeks)   ORR TRT (%)   ORR CRT (%)   Year first authorization   Official negotiated price (€)   Discounted price (€)
  --------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------- --------------------------- -------------------------- -------------------------- ------------- ------------- -------------------------- ------------------------------- ----------------------
  Teysuno         Tegafur/gimeracil/oteracil   Advanced gastric cancer in combination with cisplatin                                                                                                  Tegafur/gimeracil/oteracil\                                           5-fluorouracil 1000 mg/m^2^/24+ cisplatin 100 mg/m^2^                                                                       34.4                       31.6                                                   2011                       4942                            3479
                                                                                                                                                                                                      25 mg/m^2^+cisplatin 75 mg/m^2^                                                                                                                                                                                                                                                                                                                

  Jevtana         Cabazitaxel                  Hormone-refractory metastatic prostate cancer                                                                                                          Cabazitaxel+prednisone                                                Mitoxantrone\                                                       11.2                        5.6                         60.4                       50.8                       14.4          4.4           2011                       52 983                          38 254
                                                                                                                                                                                                                                                                            +prednisone                                                                                                                                                                                                                                                              

  Yervoy          Ipilimumab                   Advanced (unresectable or metastatic) melanoma                                                                                                         Ipilimumab+Peptide vaccin                                             Peptide vaccine glycoprotein 100 (gp100)                            11.04                       11.04                       39.8                       25.8                       5.7           1.5           2011                       71 400                          45 107

  Votubia         Everolimus                   Renal angiomyolipoma associated with tuberous sclerosis complex (TSC)                                                                                  Everolimus                                                            Placebo                                                                                         45.48                                                                             41.8          0             2011                       66 521                          41 424

  Votubia         Everolimus                   Subependymal giant cell astrocytoma associated with TSC                                                                                                Everolimus                                                            Placebo                                                                                                                                                                           34.6          0                                        53 216                          33 139

  Halaven         Eribulin                     Locally advanced or metastatic breast cancer                                                                                                           Eribulin 1.23 mg/m^2^ (equivalent to 1.4 mg/m^2^ eribulin mesylate)   Treatment of physician\'s choice                                    16.14                       9.71                        57.57                      45.86                      12.2          4.7           2011                       32 300                          28 130

  Zytiga          Abiraterone acetate          Metastatic castration-resistant prostate cancer                                                                                                        Abiraterone acetate                                                   Placebo                                                             22.4                        14.4                        68.9                       48.7                       29.1          5.5           2011                       46 842                          33 397

  Dacogen         Decitabine                   Newly diagnosed de novo or secondary acute myeloid leukaemia                                                                                           Decitabine                                                            Patient\'s choice                                                   14.8                        8.4                         30.8                       20                                                     2012                       54 366                          34 346

  Caprelsa        Vandetanib                   Aggressive and symptomatic medullary thyroid cancer unresectable locally advanced or metastatic disease                                                Vandetanib                                                            Placebo                                                             122                         77.2                                                                              45            13            2012                       67 405                          53 533

  Zelboraf        Vemurafenib                  BRAF-V600-mutation-positive unresectable or metastatic melanoma                                                                                        Vemurafenib                                                           Dacarbazine                                                         21.28                       6.44                        52.8                       39.6                       48.4          5.5           2012                       119 929                         108 236

  Xalkori         Crizotinib                   Anaplastic lymphoma kinase (ALK) positive advanced non-small-cell lung cancer (NSCLC)                                                                  Crizotinib                                                            Pemetrexed or docetaxel                                             30.8                        12                                                                                65.3          19.5          2012                       79 538                          57 427

  Xalkori         Crizotinib                   First-line treatment of adults with ALK positive advanced NSCLC                                                                                        Crizotinib                                                            Chemotherapy                                                        43.6                        28                                                                                74.4          45                                       79 538                          57 427

  Inlyta          Axitinib                     Advanced renal-cell carcinoma (RCC)                                                                                                                    Axitinib                                                              Sorafenib                                                           26.8                        18.8                                                                              19.4          9.4           2012                       57 632                          39 295

  Perjeta         Pertuzumab                   HER2-positive metastatic or locally recurrent unresectable breast cancer                                                                               Pertuzumab +trastuzumab+docetaxel                                     Placebo +trastuzumab + docetaxel                                    74                          49.6                                                                              80.2          69.3          2013                       51 643                          46 608

  Kadcyla         Trastuzumab emtansine        HER2-positive, unresectable locally advanced or metastatic breast cancer                                                                               Trastuzumab emtansine (tdm1)                                          Lapatinib +capecitabine                                             38.4                        25.6                        123.9                      100.4                                                  2013                       87 215                          75 877

  Giotrif         Afatinib                     Locally advanced or metastatic NSCLC with activating EGFR mutation(s)                                                                                  Afatinib                                                              Pemetrexed (lyophilised powder)+cisplatin (solution for infusion)   44.56                       27.6                                                                              56.1          22.6          2013                       29 528                          21 853

  Stivarga        Regorafenib                  Metastatic colorectal cancer (MCRC)                                                                                                                    Regorafenib+best supportive care                                      Placebo+best supportive care                                        8.4                         7.4                         28                         21.6                       1             0.4           2013                       85 800                          77 434

  Stivarga        Regorafenib                  Unresectable or metastatic gastrointestinal stromal tumours                                                                                            Regorafenib+best supportive care                                      Placebo+best supportive care                                        21                          4                                                                                 1.5           4.5                                      85 800                          77 434

  Tafinlar        Dabrafenib                   Unresectable or metastatic melanoma with a BRAF V600 mutation                                                                                          Dabrafenib                                                            Dacarbazine                                                         27.6                        10.8                        72.8                       62.4                       59            24            2013                       107 935                         87 670

  Zaltrap         Aflibercept                  MCRC                                                                                                                                                   Aflibercept+folfiri                                                   Placebo+folfiri                                                     27.6                        18.7                        54                         48.4                       19.8          11.1          2013                       30 576                          27 591

  Xtandi          Enzalutamide                 Metastatic castration resistant prostate cancer                                                                                                        Enzalutamide                                                          Placebo                                                             33.2                        11.6.6                      73.6                       54.4                                                   2013                       49 184                          31 960

  Imnovid         Pomalidomide                 Relapsed and refractory multiple myeloma                                                                                                               Pomalidomide+\                                                        Hd dexamethasone                                                    15.7                        8                                                      34                                                     2013                       127 985                         101 646
                                                                                                                                                                                                      Ld-dexamethasone                                                                                                                                                                                                                                                                                                                               

  Lynparza\*      Olaparib                     Platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer   Olaparib                                                              Placebo                                                             33.6                        19.2                        119.2                      111.2                                                  2014                       70 517                          52 142

  Cyramza         Ramucirumab                  Advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression                                                         Ramucirumab +paclitaxel                                               Placebo+paclitaxel                                                  17.6                        11.6                        38.4                       29.6                       27.9          16.1          2014                       87 360                          78 842

  Mekinist        Trametinib                   Unresectable or metastatic melanoma with a BRAF V600 mutation                                                                                          Trametinb                                                             Chemotherapy (dacarbazine or paclitaxel)                            19.6                        6                           62.4                       45.2                       19            5             2014                       62 398                          28 157

  Imbruvica       Ibrutinib                    Chronic lymphocytic leukaemia (CLL)                                                                                                                    Ibrutinib                                                             Chlorambucil                                                                                    75.6                                                                              82.4          35.3                                     73 805                          51 663

  Zydelig         Idelalisib                   CLL                                                                                                                                                    Idelalisib+rituximab                                                  Placebo+rituximab                                                                               22                                                                                74.5          14.5          2014                       48 667                          34 067

  Sylvant         Siltuximab                   Multicentric Castleman disease                                                                                                                         Siltuximab+best supportive care                                       Placebo+best supportive care                                                                                                                                                      37.7          3.8           2014                       66 104                          29 829

  Keytruda        Pembrolizumab                Advanced (unresectable or metastatic) melanoma                                                                                                         Pembrolizumab                                                         Ipilimumab                                                          22                          11.2                                                                              33.7          11.9          2015                       90 400                          81 586

  Opdivo          Nivolumab                    Advanced (unresectable or metastatic) melanoma                                                                                                         Nivolumab 3 mg/kg                                                     Investigator choice I                                               18.8                        16.8                                                                              31.7          10.6          2015                       81 310                          71 181

  Opdivo          Nivolumab                    Locally advanced or metastatic NSCLC                                                                                                                   Nivolumab 3 mg/kg                                                     Docetaxel 75 mg/m^2^                                                9.32                        16.8                        48.8                       37.4                       19.2          12.4                                     81 310                          71 181

  Opdivo          Nivolumab                    Advanced RCC                                                                                                                                           Nivolumab 3 mg/kg                                                     Everolimus 100 mg                                                   18.4                        17.8                        100                        78.2                       25.1          5.4                                      81 310                          in negotiation

  Lenvima         Lenvatinib mesylate          Progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma, refractory to radioactive iodine    Lenvatinib                                                            Placebo                                                             73.2                        14.4                                                                              64.8          1.5           2015                       68 433                          58 673

  Cotellic        Cobimetinib hemifumarate     Unresectable or metastatic melanoma with a BRAF V600 mutation                                                                                          Cobimetinib +vemurafenib                                              Placebo +vemurafenib                                                45.2                        24                                                                                67.6          44.8          2015                       75 374                          54 420

  Kyprolis        Carfilzomib                  Multiple myeloma who have received at least one prior therapy                                                                                          Carfilzomib +lenalidomide\                                            Lenalidomide +dexamethasone                                         105.2                       70.4                                                                              87.1          67.7          2015                       75 900                          44 525
                                                                                                                                                                                                      +dexamethasone                                                                                                                                                                                                                                                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*During the evaluation at the EMA, lymparza was found to be more effective in a subgroup of patients with a specific biomarker with the following outcome results: PFS lymparza: 44.8 w; PFS control: 17.2 w; OS lymparza: 139.6 w; OS control: 127.6.

CRT, Control Patients; EGFR, Epidermal Growth Factor Receptor; EMA, European Medicines Agency; ORR, objective response rate; OS, overall survival; PFS, progression free survival; TRT, Patients with treatment.

In the treatment groups, the median improvements in the OS and PFS were 11.4 weeks (IQR 8.8--17.2; min 13.2; max 23.5) and 12.8 weeks (IQR 6.4--17; min −7.48; max 58.8), respectively; median ORR improvement in the treatment group was 21.8% (IQR 10--34.6; min −3; max 63.3). The reported ranges have negative minimum values since in two cases---nivolumab for NSCLC and regorafenib for gastrointestinal stromal tumours---the experimental treatment had a negative effect on one of the outcomes compared with the control group (in terms of PFS for nivolumab and ORR for regorafenib). The median negotiated price for a 1-year treatment was €72 392 (IQR 53, 819--85,800; min 4,942; max 142,785), which was further discounted by 25% (on average) after applying confidential rebates. For all anticancer drugs but ipilimumab the price was calculated as 1-year treatment since the posology reported in the SPC reported that the treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs. In the case of ipilimumab, the price was calculated as a course of four doses as reported in the SPC.

The official (ex-factory) price of new anticancer drugs and absolute clinical outcomes showed no correlation ([figure 1A--C](#F1){ref-type="fig"}). The relationship between the improvement in median OS (in weeks) and negotiated price was estimated for 16 drugs (17 indications), and no correlation was observed (R^2^=0.067). When clinical outcomes were expressed as absolute advantage in median PFS or ORR, 25 drugs (29 indications) were available for analysis, and in these cases, no correlation was observed (R^2^=0.004 and 0.006, respectively).

![Correlation between anticancer drug prices (officially negotiated) and health benefits. (A) Official negotiated price (ex-factory) versus difference in median OS (16 drugs are included in the analysis: 15 with a single indication and 1 with two indications). (B) Official negotiated price (ex-factory) versus difference in median PFS (25 drugs are included in the analysis: 22 with a single indication, 2 with two indications and 1 with three indication). (C) Official negotiated price (ex-factory) versus proportion of ORR (24 drugs are included in the analysis: 20 with a single indication, 3 with two indications and 1 with three indications). OS, overall survival; ORR, objective response rate; PFS, progression-free survival.](bmjopen-2019-033728f01){#F1}

Repeating the analyses and taking into account the additional confidential rebates, which are compulsory for hospital procurement, no improvement in the benefit/price relationships was highlighted ([figure 2A--C](#F2){ref-type="fig"}). These findings also remained unchanged when the analyses were repeated with adjustments for tumour type ([online supplementary table 1](#SP1){ref-type="supplementary-material"}) or when clinical outcome was expressed as a percentage of improvement instead of as an absolute difference ([online supplementary figure 1a--c](#SP2){ref-type="supplementary-material"}). Sensitivity analyses that excluded negative improvements in outcomes over a control group ([online supplementary figure 2](#SP3){ref-type="supplementary-material"}) and considered only data from placebo-controlled trials ([online supplementary figure 3a,b](#SP4){ref-type="supplementary-material"}) confirmed the main analysis. The exploratory subgroup analyses by tumour type did not identify specific positive correlation patterns depending on tumour setting ([online supplementary figure 4A,B](#SP5){ref-type="supplementary-material"}).
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![Correlation between anticancer drug prices (discounted) and health benefits. (A) Discounted price with additional compulsory rebates versus difference in median OS (16 drugs related to a single indication are included in the analysis). (B) Discounted price with additional compulsory rebates versus difference in median PFS (25 drugs are included in the analysis: 22 with a single indication and 3 with two indications). (C) Discounted price with additional compulsory rebates versus proportion of ORR (24 drugs are included in the analysis: 20 with a single indication and 4 with two indications). OS, overall survival; ORR, objective response rate; PFS, progression-free survival.](bmjopen-2019-033728f02){#F2}

Discussion {#s4}
==========

This study is the first attempt to evaluate whether there were better correlations between cancer drug prices and clinical outcomes in a setting where central price negotiations are mandatory for every new medicine. Our study gave unexpected results to the research question, highlighting no relationships between cost of cancer drugs and benefits. Moreover, all prespecified sensitivity and subgroup analyses confirmed the main findings. This finding will have important policy implications both for countries like USA where price negotiations are absent and for other countries like Italy where price negotiations do exist.

In our study, the correlation between drug costs and clinical outcomes was even lower than the ones previously noted in the US context,[@R13] showing that negotiations did not tilt the relationship between drug prices and benefit positively. Thus, higher drug pricing remains despite the Italian legislative environment, where approval based on cost-effectiveness analysis and price negotiations have been mandatory by law since 2001.[@R15] This finding may cast doubts on the role of the negotiation itself. However, it is important to understand that countries like Italy that negotiate drug prices do such negotiations only for binary decisions of approval or no-approval, not taking into account, during negotiation, a clear correlation between prices and benefits. This understanding is important for cancer policy decisions.

Indeed, there is no legal policy in any country to negotiate prices differently for drugs approved on the basis of surrogate endpoints versus survival outcomes, or drugs that improve survival in days, versus those that improve survival in months or drugs with immature benefit risk profiles.[@R18] Although steps in the right direction, in lack of such policy, the value frameworks proposed by organisations such as ASCO, ESMO or NCCN have become little more than intellectual exercises.[@R23]

Another reason price negotiations did not achieve better price--value correlations is that because of the global market of drugs, each single country---although large---only represents a small portion of the consumer market. Thus, companies 'wield the stick', setting the maximum price that the market will bear.[@R27] In addition, in Italy, no threshold for incremental cost-effectiveness ratio (ICER) has been determined; thus, no limit is in place to be used as a decision rule in resource allocation at the time of negotiation/reimbursement decisions. The lack of such kind of cut-off might have contributed to the negative results in our study. However, we recognise that even when a threshold for ICER is well established, such as in the UK,[@R28] continuous exceptions have been allowed in the case of anticancer drugs. For example, an ad hoc fund established in 2010 (ie, the Cancer Drug Fund) was recently dismissed by the Parliament because it did not deliver meaningful value to patients or society.[@R29]

In the EU context (where newer anticancer drugs are approved by EMA without considering the added-value or cost-effectiveness), the complexity further increases because once a marketing authorisation is granted, it may become difficult to manage the reimbursement issue at a national level.[@R30] Moreover, it is also difficult for payers (NHS/insurance) to defend the thesis against the public opinion that an anticancer drug cannot be reimbursed because it is too expensive.[@R30] Indeed, as our study shows, the confidential discounts following negotiations between a member state and a company do not ameliorate the correlation between treatment costs and benefits even though they reduce absolute drug prices.

Another factor that negatively influences the contractual power of negotiation is non-transparent information on drug prices across countries. Difficulties in retrieving full information on prices have been already recognised in a recent survey comparing prices of anticancer drugs in 16 EU countries, Australia and New Zealand.[@R32] Vogler *et al* found that price information is scarce and not disclosed due to confidential discounts or managed entry agreements (MEAs), calling for higher transparency. The authors state that it is in the interest of policy-makers to remove clauses limiting disclosure on price information because they risk overpaying when setting prices through external price referencing. This concern might be relevant in the Italian context since the negotiation procedure for reimbursement takes into account the price in other EU countries as well as the price of similar products within the same pharmacotherapeutic group.[@R33]

We believe that two partly independent approaches could be adopted by policy-makers to achieve a better balance between cancer drug prices and benefits. First, price negotiations should be more strictly based on the level of evidence as well as the magnitudes of benefit. An ICER measure (such as QALY) should represent a threshold for reimbursement, thus setting a starting point for price negotiation and adjusting the ICER threshold based on the magnitude of the relative benefit reached. If the information on the relative value is not available at the time of approval, comparisons can be performed using indirect techniques, whereas after entering the market, payers should play a major role in supporting the evidence generating process.

The second approach that could attain lower prices would require an increased transparency on the costs of drug development process, including the relative contributions from academia and public sector to the development of a drug.[@R34] For instance, research conducted to evaluate efforts of drug development processes highlighted that about half of the most transformative drugs approved by the FDA had substantial contributions to their development by academic researchers supported by government funding[@R34]; in addition, it has been estimated that the cost of late clinical development takes a limited part of the whole process.[@R36] It is probably the right time to appropriately acknowledge the contributions of publicly funded research during drug price negotiation with companies. Often, comparative effectiveness research is funded by public institutions to test different treatments in real practice on robust outcomes with longer follow-up or special populations.[@R37] The findings of these studies should be linked to a continuous price renegotiation over the life cycle of a product.

Other approaches identified as possible solutions to keep the health system sustainable address the general governance of the system, that is, when the price is already set. In fact, a price-volume approach[@R39] or indication-based pricing[@R40] have been modelled, each presenting pros and cons. Moreover, given that different oncology settings appear to be oligopolistic, thus refraining from price competition, another possible solution comes from national/regional tenders among therapeutic categories when more alternatives are available.[@R42]

The main limitations of our study concern data completeness on clinical outcome and price. We used, as an estimate of benefit, data from pivotal trials retrieved from EPARs. Moreover, we are not aware if further (more robust) data became available at a later stage when the price was negotiated at the national level. Thus, we cannot exclude that the correlation between drug prices and therapeutic benefit might improve taking into account data acquired after the marketing of anticancer drugs.

Another important limitation is that we have not considered quality of life outcomes as another metric of clinical benefit. Furthermore, a recent study has shown that quality of life outcomes are not routinely collected or published, and that the tools used to measure quality of life are varied to have a uniform metric for comparison.[@R43] Although we have included surrogate measures such as PFS or ORR as clinical outcomes in our analysis because they were considered as the basis for approval by the regulatory agency, these surrogate measures do not always correlate with true clinical benefits in terms of improved survival or improved quality of life.[@R43] Regarding the price estimate, we estimated the treatment costs for 1-year treatment or for the total course in the case of ipilimumab where the treatment course lasts less than 1 year. However, the exclusion of ipilimumab would not alter the main findings.

Another factor that might have impacted the price estimation is the rebate obtained at the regional/local level following drug tenders. This information was not available for the analyses and would have been not generalisable at the national level. Moreover, additional savings were expected 'a posteriori' from the MEAs in place in Italy (whose information is not publicly available) and were not considered in the analyses.

Our study is a retrospective cross-sectional correlation study that aimed at evaluating whether central price negotiation (mandatory by law in Italy) leads to better alignment of prices and the benefits known at the time of drug approval. This means that our analysis is not aimed at comparing costs and outcomes within drug classes, as a typical cost-effective study, and we never intended to assess the added values of the approved drugs in the context of all other drugs sharing the same indication. The 'population'/cohort approach that we adopted has the intrinsic limitation of including drugs approved for different indications or different cancer types (with various incidence/prevalence) based on different clinical data packages. The consequent heterogeneity stemming from this approach was resolved adjusting the correlation analyses by tumour type or conducting several subanalyses. Following this approach, we found results consistent with primary findings thus confirming the robustness of methods and results.

Conclusion {#s5}
==========

Our results suggest that price negotiations for approval decisions alone may not bring balance between prices and benefits of anticancer drugs. Based on the limited outcome data available at the time of reimbursement decisions (OS, PFS and ORR), prices of anticancer drugs do not reflect their therapeutic benefit. Other strategies, such as value-based price negotiations, price negotiations strictly based on strength of evidence and price transparencies may be necessary to better achieve the drug prices and benefits balance. These results need to be confirmed in other countries where a national price negotiation exists.
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